Patupilone (EPO906, Epothilone B)

Catalog No.S1364

Patupilone (EPO906, Epothilone B) Chemical Structure

Molecular Weight(MW): 507.68

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.

Size Price Stock Quantity  
In DMSO USD 250 In stock
USD 70 In stock
USD 120 In stock
USD 210 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Matrigel invasion assay of H1299 cells treated with SDF-1α or SDF-1α plus Epothilone B prior to 0 or 2 Gy irradiation. After the treatment for 12 h, the H1299 cells that migrated to the bottom surface of the membrane were stained with Giemsa, and the number of migrated cells was calculated manually.

    Oncotarget, 2015, 6(13):10893-907.. Patupilone (EPO906, Epothilone B) purchased from Selleck.

    Combination treatment with epothilone B and ABT-737 inhibited PI3K/AKT/mTOR pathway. SKOV-3 cells were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination, OVCAR-8 cells were treated with epothilone B (0.3 nM), ABT-737 (3 μM), or the combination, SGC-7901 were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination. Cells were exposed to compounds for 48 h, after which protein extracts were immunoblotted with specified antibodies for p-4E-BP-1, p-mTOR, p-AKT, caspase-3, PARP and β-actin.

    J Cancer Res Clin Oncol, 2016, 142(11):2281-9.. Patupilone (EPO906, Epothilone B) purchased from Selleck.

  • Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Epothilone B for 48 h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Patupilone (EPO906, Epothilone B) purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.
Targets
Tubulin [1]
(Cell-free assay)
1.8 μM(EC0.01)
In vitro

Epothilone B shows better activity than Epothilone A. The EC0.01 of Epothilone B is 1.8 μM. Epothilone B potently inhibits cell proliferation in HCT116 cells, with IC50 of 0.8 nM. [1] Epothilone B induces mitotic arrest and displays cytotoxicity in KB3-1, KBV-1, Hela, and Hs578T cells, with IC50 of 3 nM to 92 nM. Epothilone B competes with Taxol in binding to microtubules, with IC50 of 3.3 μM. [2] In MCF-7 cells overexpressing GFP-α-tubulin, Epothilone B (3.5 nM) efficiently blocks microtubule dynamics. Meanwhile, Epothilone B induces mitotic arrest with IC50 of 3.5 nM. [3] In multiple myeloma (MM) cells, including RPMI 8226, U266, MM.1S, LR5, and MR20, Epothilone B directly suppresses proliferation with IC50 of 1 nM to 10 nM. Similarly, Epothilone B (10 nM) also induces cell cycle arrest and apoptosis. [4] A recent study reveals that, in ovarian cancer Hey cells, Epothilone B (5 nM–100 nM) enhances surface epithelial cell adhesion antigen (EpCAM), without affecting the transcription or the total cellular level of EpCAM. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human LC-2-ad cell M2i4e2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGxENTJvYXSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlc4\S1yNjFOwG0> NIH2WZJUSU6JRWK=
human A431 cell NIfubHNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGnjeVZKdmirYnn0bY9vKG:oIHj1cYFvKEF2M{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25Mlg3\S1yNjFOwG0> Mo\MV2FPT0WU
human SW1710 cell NGLm[4FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NE[4WoFKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOTSnLUC1JO69VQ>? M1HPbHNCVkeHUh?=
human Daoy cell NEO5[WZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4npfGlvcGmkaYTpc44hd2ZiaIXtZY4hTGGxeTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H589yNKEmFNUC9Nk44O2VvMEWg{txO MYXTRW5ITVJ?
human BFTC-905 cell M1zsRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYTPepZXUW6qaXLpeIlwdiCxZjDoeY1idiCERmTDMVkxPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwOUnlMVA2KM7:TR?= NYnCbot6W0GQR1XS
human A375 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWDJcohq[mm2aX;uJI9nKGi3bXHuJGE{PzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13ZT2wOUDPxE1? MljrV2FPT0WU
human RKO cell NUHsdZFlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnTITY5pcWKrdHnvckBw\iCqdX3hckBTU09iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkS3[U0xPSEQvF2= MWXTRW5ITVJ?
human KYSE-510 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWHJcohq[mm2aX;uJI9nKGi3bXHuJGt[W0VvNUGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4{QGVvMEWg{txO M2TYcnNCVkeHUh?=
human HLE cell M1TSOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVHJcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRThwMk\lMVA2KM7:TR?= MlnIV2FPT0WU
human MCF7 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGLofmJKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlY3\S1yNTFOwG0> M4LOUnNCVkeHUh?=
human 786-0 cell NUTKe|VkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUHJcohq[mm2aX;uJI9nKGi3bXHuJFc5Pi1yIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNUBvVQ>? MWLTRW5ITVJ?
human TE-8 cell M1T4Nmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoTKTY5pcWKrdHnvckBw\iCqdX3hckBVTS16IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNVEhdk1? NUfVXnNDW0GQR1XS
ovarian carcinoma 1A9 cell M1rlT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3TjNGlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDh[4FqdnO2IH;2ZZJq[W5iY3HyZ4lvd22jIEHBPUBk\WyuIHfyc5d1cA>? M1LYOFE3OTN2OUK4
human PANC-03-27 cell M{G3SWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3HmVmlvcGmkaYTpc44hd2ZiaIXtZY4hWEGQQz2wN{0zPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUOyJO69VQ>? MVzTRW5ITVJ?
human VMRC-RCZ cell M{GyR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVjJcohq[mm2aX;uJI9nKGi3bXHuJHZOWkNvUlPaJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOzZizszN MknCV2FPT0WU
human IGROV-1 cell M1ixbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2\YcmlvcGmkaYTpc44hd2ZiaIXtZY4hUUeUT2[tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTV4IN88US=> MVHTRW5ITVJ?
human MG-63 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV7Jcohq[mm2aX;uJI9nKGi3bXHuJG1INTZ|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xOlUh|ryP MoHIV2FPT0WU
human SIG-M5 cell MkjyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFvqS4VKdmirYnn0bY9vKG:oIHj1cYFvKFOLRz3NOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTZ7IN88US=> NXHOUXF7W0GQR1XS
human NCI-H650 cell NUfBUHV7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mme0TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSE[1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTdizszN MkH0V2FPT0WU
human PSN1 cell M4D6Zmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYnJcohq[mm2aX;uJI9nKGi3bXHuJHBUVjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG3N{DPxE1? M1jZT3NCVkeHUh?=
human PA-1 cell M1zxcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGPZZmtKdmirYnn0bY9vKG:oIHj1cYFvKFCDLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE4PCEQvF2= NWrnT49tW0GQR1XS
KB-8511 cells NI\LZ3BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2fCNFczKGh? Ml65R49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IITo[UBoem:5dHigc4YheGGlbHn0ZZhmdC2{ZYPpd5RidnRiaIXtZY4h\XCrZHXycY9q\CClYYLjbY5wdWFiY3XscJMhU0JvOEWxNUBjgSB3MDDw[ZJk\W62IDi3NkBpeiCneIDvd5Vz\SluIFnDOVA:OC5zODFOwG0> MmW1NVEyOzNyOE[=
KB-31 cells NFvVVYtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3Sy[FczKGh? Ml3nR49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IITo[UBoem:5dHigc4YheGGlbHn0ZZhmdC2|ZX7zbZRqfmViaIXtZY4h\XCrZHXycY9q\CClYYLjbY5wdWFiY3XscJMhU0JvM{GgZpkhPTBicHXyZ4VvfCBqN{KgbJIh\Xiyb4P1doUq MWCxNVE{OzB6Nh?=
human BHY cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4XoeWlvcGmkaYTpc44hd2ZiaIXtZY4hSki\IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xPVUhdk1? M2DXUHNCVkeHUh?=
human BB30-HNC cell M1;n[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2[xVmlvcGmkaYTpc44hd2ZiaIXtZY4hSkJ|MD3IUmMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJyMTFOwG0> MmDCV2FPT0WU
human HOS cell Mo\CS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGfWbHZKdmirYnn0bY9vKG:oIHj1cYFvKEiRUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlE2KM7:TR?= NVmweGVRW0GQR1XS
human 639-V cell NH31[JJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEX5enpKdmirYnn0bY9vKG:oIHj1cYFvKDZ|OT3WJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOThizszN MYHTRW5ITVJ?
human ES1 cell  MkPDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUXJcohq[mm2aX;uJI9nKGi3bXHuJGVUOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkKxJO69VQ>? NHjPNZpUSU6JRWK=
human TE-15 cell  NHXYWmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXLJcohq[mm2aX;uJI9nKGi3bXHuJHRGNTF3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNlUh|ryP NVPs[GdwW0GQR1XS
human LXF-289 cell NGD0UHJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWO5e3F3UW6qaXLpeIlwdiCxZjDoeY1idiCOWF[tNlg6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{N{eg{txO MmTDV2FPT0WU
human CAL-12T cell NIS2OoFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmPuTY5pcWKrdHnvckBw\iCqdX3hckBESUxvMULUJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOzlizszN NV\hOZQ2W0GQR1XS
human T84 cell MlmyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXTJcohq[mm2aX;uJI9nKGi3bXHuJHQ5PCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkSg{txO MWDTRW5ITVJ?
human KYSE-450 cell M1[yXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnzITY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUS1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjZ5IN88US=> NHS2fmdUSU6JRWK=
human LCLC-103H cell NFHy[GRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnrXTY5pcWKrdHnvckBw\iCqdX3hckBNS0yFLUGwN2gh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjNzIH7N M4Dk[XNCVkeHUh?=
human NCI-H810 cell MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWPHeo5IUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFgyOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{KyJO69VQ>? MonSV2FPT0WU
human HUTU-80 cell NGnwUHpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3fRemlvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzJ6IN88US=> M1\odXNCVkeHUh?=
human NCI-H460 cell MojGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVf3TYp{UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFQ3OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{OzJO69VQ>? M3jjXHNCVkeHUh?=
human HGC-27 cell M2HBWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHuyfphKdmirYnn0bY9vKG:oIHj1cYFvKEiJQz2yO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN6IN88US=> MY\TRW5ITVJ?
human HSC-2 cell NVrJVmNOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3jTVmlvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM3OyCwTR?= NUXPbHFtW0GQR1XS
human IA-LM cell M12zVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M121dGlvcGmkaYTpc44hd2ZiaIXtZY4hUUFvTF2gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM6OyEQvF2= MnXXV2FPT0WU
human HMV-II cell M1[2cWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4K0dmlvcGmkaYTpc44hd2ZiaIXtZY4hUE2YLVnJJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QTRizszN NHf0[WNUSU6JRWK=
human COLO-679 cell NY\XR3g3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWLJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vNke5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QTRizszN NV:xUGdpW0GQR1XS
human NCI-H2122 cell M1;NPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH3lVlNKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlEzOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNEGg{txO M3O2bnNCVkeHUh?=
human CAL-39 cell NXznNWtHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYLHR2ZqUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytN|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjRzMTFOwG0> NXLofoh1W0GQR1XS
human SW954 cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkHXTY5pcWKrdHnvckBw\iCqdX3hckBUXzl3NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFM3KM7:TR?= MVvTRW5ITVJ?
human LCLC-97TM1 cell NG\lO2dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml\pTY5pcWKrdHnvckBw\iCqdX3hckBNS0yFLUm3WG0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52NESg{txO NYe5UWl5W0GQR1XS
human KYSE-270 cell MnrhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnjGTY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUK3NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDR3IN88US=> MkewV2FPT0WU
human NB13 cell M2S1TWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M13zPGlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFQ4KM7:TR?= MlziV2FPT0WU
human SK-LMS-1 cell NVHB[o1oT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYrUfWV7UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3MUXMuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNkS2JO69VQ>? M1\a[nNCVkeHUh?=
human SW620 cell NGjpc4xIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVvJcohq[mm2aX;uJI9nKGi3bXHuJHNYPjJyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD62OFgh|ryP MVHTRW5ITVJ?
human HCT-15 cell NFXxc4ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGhEXC1zNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|E4KM7:TR?= MVjTRW5ITVJ?
human DU-145 cell MoPmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGRWNTF2NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|IyKM7:TR?= M1ruTXNCVkeHUh?=
human ST486 cell NEHpS3hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVzsT3VVUW6qaXLpeIlwdiCxZjDoeY1idiCVVES4OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzJzIN88US=> MXHTRW5ITVJ?
human A427 cell MnTaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWLJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkiyPEDPxE1? NXHuXFF{W0GQR1XS
human HT-1080 cell NGTO[mNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFzRXmZKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh2MjFOwG0> MUfTRW5ITVJ?
human NCI-H2009 cell NEDFUlRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHzTfXVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlAxQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOE[yJO69VQ>? MWLTRW5ITVJ?
human SK-LU-1 cell NXLPd|B3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYLJcohq[mm2aX;uJI9nKGi3bXHuJHNMNUyXLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg3PiEQvF2= MojSV2FPT0WU
human SCC-4 cell NUXB[phST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUfJcohq[mm2aX;uJI9nKGi3bXHuJHNESy12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD64O|ch|ryP MV\TRW5ITVJ?
human NCI-H1299 cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NELkVIVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVI6QSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOEig{txO M{HubXNCVkeHUh?=
human NH-12 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mkn6TY5pcWKrdHnvckBw\iCqdX3hckBPUC1zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPFkyKM7:TR?= M3uwdXNCVkeHUh?=
human SK-UT-1 cell M3zmS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF3tUlBKdmirYnn0bY9vKG:oIHj1cYFvKFONLWXUMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh7MjFOwG0> M3:5NnNCVkeHUh?=
human Bel7402 M{KzOXBzd2yrZnXyZZRqd25iYYPzZZk> NEDaOnY4OiCq MWnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEKnbEe0NFIh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTldkBIdG9iYYPzZZktKEmFNUC9NE46KM7:TR?= NVjLWmVDOjJ|MkCzOVQ>
human A388 cell NHrq[XlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWOyU4cyUW6qaXLpeIlwdiCxZjDoeY1idiCDM{i4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46PCEQvF2= NXrTNHpGW0GQR1XS
human SW982 cell NI\CO3hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYrJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65PVkh|ryP NVHZRoR4W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo In a mouse xenograft model of RPMI 8226 cells, Epothilone B (2.5 mg/kg–4 mg/kg) prolongs survival and suppresses tumor growth. [4] Similarly, in mouse xenograft models of prostate cancer cells, including DU145 and PC3, Epothilone B at the same dose also inhibits tumor growth. [6]

Protocol

Kinase Assay:[1]
+ Expand

Tubulin polymerization assay:

Calf brain microtubule proteins (MTP) are purified, which includes approximately 15%–20% microtubule associated proteins. The buffer (MES buffer) used for the Epothilone B-microtubule studies contains 0.1 M 2-morpholinoethanesulfonic acid (MES), 1 mM EGTA, 0.5 mM MgCl2, and 3 M glycerol at pH 6.6. Samples for electron microscopy are placed on carbon-over-Parlodion-coated grids (300 mesh) and negatively stained with 2% uranyl acetate. Microtubule assembly in the presence or absence of Epothilone B is monitored spectrophotometrically by using a spectrophotometer equipped with a thermostatically regulated liquid circulator. The temperature is held at 35 °C and changes in turbidity (representative of polymer mass) are monitored at 350 nm. Effective concentration (EC0.01), defined as the interpolated concentration capable of inducing an initial slope of 0.01 OD/min rate, is calculated using the formula EC0.01 = concentration/slope and expressed as the mean with standard deviation obtained from three different concentrations.
Cell Research:[2]
+ Expand
  • Cell lines: KB3-1, KBV-1, Hela, and Hs578T cells
  • Concentrations: 0–1 μM
  • Incubation Time: 72 hours
  • Method: For mitotic block and aberrant mitosis, cells are plated either in 48-well plates (for trypan blue and cell counting) or onto coverslips. After 24 hours, cells are treated with Epothilone B and scored at regular intervals. For the cytotoxicity analysis, cells are counted and scored as trypan blue positive or negative. Concurrently, coverslips andaliquots of cells in the culture supernatant are fixed and stained with Hoechst33342 in PBS. These cells are scored for cells blocked at the G2/M transition and aberrant mitosis.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Mice xenograft model of RPMI 8226 cells
  • Formulation: Dissolved in30% PEG-300
  • Dosages: 2.5 mg/kg–4 mg/kg
  • Administration: Inject intravenously
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 102 mg/mL (200.91 mM)
Ethanol 102 mg/mL (200.91 mM)
Water Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 507.68
Formula

C27H41NO6S

CAS No. 152044-54-7
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00715013 Completed Recurrent Glioblastoma Planned for Reoperation University of Zurich July 2008 Phase 1|Phase 2
NCT00442741 Withdrawn Solid Tumors Novartis Pharmaceuticals|Novartis July 2007 Phase 1
NCT00496600 Completed Refractory Malignancy University of Medicine and Dentistry of New Jersey|Novartis Pharmaceuticals|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey July 2007 Phase 1
NCT00468260 Terminated Advanced Malignancies Novartis Pharmaceuticals|Novartis May 2007 Phase 1
NCT00448396 Completed Advanced Malignancies Novartis Pharmaceuticals|Novartis March 2007 Phase 1
NCT00407251 Completed Hormone Refractory Prostate Cancer British Columbia Cancer Agency February 2007 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Patupilone (EPO906, Epothilone B) | Patupilone (EPO906, Epothilone B) supplier | purchase Patupilone (EPO906, Epothilone B) | Patupilone (EPO906, Epothilone B) cost | Patupilone (EPO906, Epothilone B) manufacturer | order Patupilone (EPO906, Epothilone B) | Patupilone (EPO906, Epothilone B) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID